Belantamab mafodotin (belamaf; GSK2857916) US expanded access program (EAP) for heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Baseline characteristics Meeting Abstract
| Authors: | Hultcrantz, M.; Anderson, L. D. Jr; Anwer, F.; Gasparetto, C.; Kocoglu, M. H.; Lichtman, E. I.; Mo, C.; Niesvizky, R.; Lewis, E.; Li, H.; Paul, S.; Petrone, S.; Kaufman, J. L. |
| Abstract Title: | Belantamab mafodotin (belamaf; GSK2857916) US expanded access program (EAP) for heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Baseline characteristics |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | expanded access program; mm; relapsed/refractory multiple myeloma |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S439 |
| End Page: | S440 |
| Language: | English |
| ACCESSION: | WOS:000691910500417 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01979-0 |
| Notes: | Meeting Abstract: MM-392 -- Source: Wos |
